2013-03-01 16:54:43 - Recently published research from GlobalData, "PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022", is now available at Fast Market Research

GlobalData has released its new Country report, "PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022". The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J's Zytiga (abiraterone acetate) and Medivation/Astellas' Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naive mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer,

androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.


Full Report Details at
- www.fastmr.com/prod/544165_pharmapoint_prostate_cancer_italy_dru ..


In Italy, prostate cancer is diagnosed in response to symptoms, an abnormal DRE, or an elevated PSA level found during routine screening (EAU, 2012). Routine PSA screening is used less frequently in Italy than in most major markets, similar to the UK. A diagnosis is confirmed using TRUS-guided core needle biopsies, and metastases are detected using a bone scan, CT scan, or Positron Emission Tomography (PET) choline scan. Prescribers and KOLs do not expect to see major changes in how prostate cancer is diagnosed over the forecast period, and do not believe the USPSTF recommendation against routine PSA screening will have an impact in Italy.

Scope

* Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Italy from 2012 to 2022.
* Analysis of the impact of key events as well the drivers and restraints affecting the Italy Prostate cancer market.

Reasons to buy

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in Italy
* Obtain sales forecast from 2012-2022 in Italy

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Diagnosis and Referral Overview
4.2 Treatment Overview
4.2.1 Conservative Management Strategies
4.2.2 Localized Treatments
4.2.3 Hormone Therapy
4.2.4 Drug Therapies
4.3 Italy
4.3.1 Diagnosis
4.3.2 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profiles - Major Brands, Hormone Therapies
5.3.1 Zoladex (goserelin acetate)
5.3.2 Lupron Depot (leuprolide acetate)
5.3.3 Eligard (leuprolide acetate)
5.3.4 Trelstar (triptorelin acetate)
5.3.5 Firmagon (degarelix)
5.3.6 Casodex (bicalutamide)
5.4 Product Profiles - Major Brands, Chemotherapies
5.4.1 Taxotere (docetaxel)
5.4.2 Jevtana (cabazitaxel)
5.5 Product Profiles - Major Brands, Therapeutic Vaccines
5.5.1 Provenge (sipuleucil-T)
5.6 Product Profiles - Major Brands, Targeted Therapies
5.6.1 Zytiga (abiraterone acetate)
5.6.2 Xtandi (enzalutamide)
5.7 Product Profiles - Major Brands, Bone Therapies
5.7.1 Xgeva (denosumab)
5.7.2 Zometa (zoledronic acid)
5.8 Other Marketed Hormone and Drug Therapies
6 Opportunity and Unmet Need
6.1 Overview
6.2 Efficacy at Prolonging Overall Survival
6.3 Safety
6.4 Mitigation of Symptoms
6.5 Cost
6.6 Convenient Routes of Administration
6.7 Accurate Diagnostic Tests and Surveillance Tools
6.8 Unmet Needs Gap Analysis
6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development
7.2.1 Cabozantinib
7.2.2 Custirsen Sodium
7.2.3 Sprycel (dasatinib)
7.2.4 Yervoy (ipilimumab)
7.2.5 Orteronel
7.2.6 Alpharadin (radium-223 chloride)
7.2.7 Tasquinimod
7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM)
8 Market Outlook
8.1 Italy
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment
9.4.2 Percent Drug-treated Patients
9.4.3 Percent Hormone Therapy-Treated Patients
9.4.4 Drugs Included in Each Therapeutic Class
9.4.5 Launch, Patent and Market Exclusivity Expiry Dates
9.4.6 General Pricing Assumptions
9.4.7 Individual Drug Assumptions
9.4.8 Generic Erosion
9.4.9 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in This Study
9.6 Survey of Prescribing Physicians
9.7 About the Authors
9.7.1 Authors
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Contact Us
9.10 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets
Table 2: Global Variations in Recommendations on Routine PSA Screening

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=544165&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.